See main article: COVID-19 pandemic in Spain.
| Native Name Lang: | Spanish |
| Date: | – present |
| Location: | Spain |
| Cause: | COVID-19 pandemic in Spain |
| Target: | Adult population (age 12+) and children (age 5+) |
| Organisers: | Ministry of Health |
| Participants: | 40.911.451 people |
| Outcome: | [1] (46,2% with booster dose) |
| Website: | Gobierno de España |
| Notes: | Updated in |
The COVID-19 vaccination in Spain is the national vaccination strategy started on 27 December 2020 in order to vaccinate the country's population against COVID-19 within the international effort to fight the COVID-19 pandemic.
As of November 23, 2021, the following doses had been received: 59,296,575 Pfizer–BioNTech COVID-19 vaccine doses, 16,105,300 Moderna vaccine doses, 17,427,500 Oxford–AstraZeneca vaccine doses and 2,659,000 Janssen vaccine doses, totaling to 95,488,375 doses. Out of these doses, 75,173,640 had been administered.
The autonomous communities with the highest fully-vaccinated percentage are Asturias (85.1%) and Galicia (84.9%), while the communities with the lowest percentage are the Canary Islands (75.7%) and the Balearic Islands (72.4%). The Spanish average percentage was 79.1%, amounting to 37,557,243 people.
Out of the total, 3,776,118 have been administered as additional doses, or third doses, of which 3,319,229 are Pfizer–BioNTech COVID-19 vaccine doses and 456,889 are Moderna vaccine doses.
The amount of doses ordered from Q1 to Q4 of 2021 is 141,943,261.
There are several COVID-19 vaccines at various stages of development around the world.
| Pfizer–BioNTech | 146 million | 12+ | |||
| Moderna | 52 million | 12+ | |||
| Oxford-AstraZeneca | 31 million | 60–69 | |||
| Janssen | 20 million | 40+ | |||
| Novavax | 2,2 million | ||||
| Valneva | |||||
| Sanofi–GSK | |||||
| CureVac |
According to the Government of Spain, the vaccination campaign, which is being carried out voluntarily, is structured in four phases. These phases are at the same time formed by different population groups defined in the National COVID-19 Vaccination Strategy :[3]
| Phases | Population group | Development | |||
|---|---|---|---|---|---|
| 1st doses | 2nd doses | ||||
| 0 | Development, approval and assessment. | ||||
| 1 | Priority groups | Elderly and disabled care homes' residents and staff | Completed (99,3%) | Completed (92,0%) | |
| First line health and socio-sanitary professionals | Completed | Completed | |||
| Other health and socio-sanitary professionals | Completed | Completed | |||
| Highly dependent people not living in care homes | Completed | Completed | |||
| 2 | Other priority groups | All those aged 80 and older | >100,0% | >100,0% | |
| All those aged between 70 and 79 and those with very high risk conditions | 99,1% | 98,2% | |||
| All those aged between 60 and 69 | 97,9% | 95,1% | |||
| Other health and socio-sanitary professionals | Completed | Completed | |||
| Workers with an essential social role | Completed | Completed | |||
| All those aged between 50 and 59 | 97,4% | 93,1% | |||
| 3(In progress) | Rest of priority groups | All those aged between 40 and 49 | 88,9% | 85,6% | |
| All those aged between 30 and 39 | 74,4% | 72,7% | |||
| All those aged between 20 and 29 | 73,0% | 70,0% | |||
| All those aged between 12 and 19 | 80,7% | 77,2% | |||
| TOTALS | |||||
| Current prioritary goal (all those aged 40 and over) | 94,2% | 92,1% | |||
| Target population (all those aged 12 and over) | 90,8% | 85,5% | |||
| Spanish total population | 79,5% | 77,3% | |||
According to the Centre for Sociological Research, the Spanish public organism in charge of investigating the public opinion of the society on many different topics, these are the data of the acceptance of the vaccine among the Spanish population:
| YES | Yes | 40,2% | 36,8% | 40,5% | 72,5% | 82,9% | 82,5% | 70,4% | 53,2% | 37,8% | |
| They are already vaccinated | – | – | – | – | – | 5,1% | 15,0% | 37,7% | 55,1% | ||
| Yes, depending on the origin of the vaccine | 0,2% | 0,1% | 0,6% | 0,2% | 0,4% | 0,6% | 2,4% | 1,2% | 0,4% | ||
| Yes, if there are guarantees, if it is proven, if it is reliable | 2,2% | 1,4% | 16,2% | 2,5% | 1,8% | 0,9% | 1,6% | 0,5% | 0,2% | ||
| Yes, on the advice of the authorities, scientists or health professionals | 0,2% | 0,3% | 3,6% | 1,3% | 0,9% | 0,3% | 0,4% | 0,3% | 0,1% | ||
| Yes, if there is enough information | 0,2% | 0,0% | 3,2% | 0,8% | 0,4% | 0,2% | 0,3% | 0,2% | 0,1% | ||
| TOTAL YES | 43,0% | 38,6% | 64,1% | 77,3% | 86,4% | 89,6% | 90,1% | 93,1% | 93,7% | ||
| NO | No | 43,8% | 47,0% | 28,0% | 16,5% | 6,5% | 5,4% | 5,3% | 3,7% | 3,6% | |
| TOTAL NO | 43,8% | 47,0% | 28,0% | 16,5% | 6,5% | 5,4% | 5,3% | 3,7% | 3,6% | ||
| NK+ NA | Does not know, doubts | 12,4% | 13,4% | 5,3% | 4,5% | 5,5% | 3,8% | 3,3% | 2,4% | 1,8% | |
| Other answers | 0,6% | 0,7% | 2,5% | 1,7% | 1,6% | 1,0% | 1,3% | 0,7% | 0,6% | ||
| N.A. (Not answers) | 0,4% | 0,3% | 0,1% | 0,1% | 0,1% | 0,0% | 0,1% | 0,0% | 0,1% | ||
| TOTAL NK/NA (OTHER ANSWERS) | 13,4% | 14,4% | 7,9% | 6,3% | 7,2% | 4,8% | 4,7% | 3,1% | 2,5% | ||
| Sample | 2.924 | 3.853 | 3.817 | 3.852 | 3.869 | 3.820 | 3.823 | 3.814 | 3.814 | ||
| Reference | [4] | [5] | [6] | [7] | [8] | [9] | [10] | [11] | [12] | ||
From February 2021 onwards, the centre began to ask among those who did not want to take the vaccine about the reasons they had for choosing not to receive the shot, obtaining the following results:
| March 2021 | April 2021 | May 2021 | June 2021 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| % question | % total sample | % question | % total sample | % question | % total sample | % question | % total sample | % question | % total sample | ||
| They do not rely on these vaccines | 31,2% | 2,0280% | 29,3% | 1,5822% | 34,6% | 1,8338% | 25,3% | 0,9361% | 35,4% | 1,2744% | |
| Because of fear to develop risks for their health/side-collateral effects | 18,5% | 1,2025% | 20,1% | 1,0854% | 25,3% | 1,3409% | 25,3% | 0,9361% | 15,6% | 0,5616% | |
| They are against all vaccines in general | 4,3% | 0,2795% | 1,7% | 0,0981% | 3,1% | 0,1643% | 4,4% | 0,1628% | 7,1% | 0,2556% | |
| They prefer to wait to see how they work | 9,2% | 0,5980% | 6,0% | 0,3240% | 3,5% | 0,1855% | 7,7% | 0,2849% | 6,9% | 0,2484% | |
| They do not believe they are effective | 8,3% | 0,5395% | 7,1% | 0,3834% | 5,2% | 0,2756% | 8,7% | 0,3219% | 5,2% | 0,1872% | |
| They do not consider it necessary (without specifying) | – | – | 4,6% | 0,2484% | 3,7% | 0,1961% | 7,3% | 0,2701% | 4,7% | 0,1692% | |
| Because of lack of guarantees: few trials, earliness, lack of analysis | 4,6% | 0,2990% | 4,6% | 0,2484% | 3,7% | 0,1961% | 4,2% | 0,1554% | 3,1% | 0,1116% | |
| COVID-19 denial | – | – | 3,1% | 0,1674% | 2,8% | 0,1484% | 0,7% | 0,0259% | 3,1% | 0,1116% | |
| Because of having few possibilities of infection | 3,2% | 0,2080% | 3,5% | 0,1890% | 1,0% | 0,0530% | 4,8% | 0,1776% | 3,0% | 0,1080% | |
| Because of having allergies, other diseases or treatments, breastfeeding, pregnancy | 3,0% | 0,1950% | 2,1% | 0,1134% | 3,6% | 0,1908% | 3,7% | 0,1369% | 2,3% | 0,0828% | |
| Because of having passed COVID-19 | – | – | 4,6% | 0,2484% | 3,4% | 0,1802% | 0,2% | 0,0074% | 2,2% | 0,0792% | |
| Because of lack of information | 1,5% | 0,0975% | 3,7% | 0,1998% | 1,1% | 0,0583% | 0,7% | 0,0259% | 1,4% | 0,0504% | |
| There are other people more vulnerable or with a higher risk than them | 0,8% | 0,052% | 1,0% | 0,0540% | – | – | – | – | 0,8% | 0,0288% | |
| They do not ever get vaccinated | 1,0% | 0,0650% | 1,5% | 0,0810% | 1,6% | 0,0848% | 1,5% | 0,0555% | - | - | |
| Because of any other reason | 12,9% | 0,8385% | 4,9% | 0,2646% | 5,8% | 0,3074% | 3,1% | 0,1147% | 7,3% | 0,2628% | |
| They do not know, doubt | 1,3% | 0,0845% | 1,9% | 0,1026% | 1,0% | 0,0530% | 1,8% | 0,0666% | - | - | |
| N.A. (Not answers) | 0,2% | 0,0130% | – | – | 0,5% | 0,0265% | 0,8% | 0,0296% | 1,9% | 0,0684% | |
| Sample | 251 | 3.869 | 208 | 3.820 | 203 | 3.823 | 143 | 3.814 | 138 | 3.814 | |
| Reference | |||||||||||
The progress of the vaccination campaign to more and more demographic groups has allowed many public figures to receive one or two doses of the vaccine correspondent to them by age or belonging to some other priority group.